Journal of Clinical Oncology
Articles in this Issue
Psychosocial digital application for caregivers of patients undergoing hematopoietic stem cell transplantation (HSCT): A randomized controlled trial.
11000 Background: Caregivers (i.e., relatives and friends) of patients undergoing HSCT struggle with considerable quality of life (QOL) impairments and ps...
Tislelizumab as monotherapy or in sequential combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma: A prospective, phase II clinical study.
e16292 Background: Neoadjuvant immunotherapy represents a potential approach to improve the post-surgical prognosis of res...
Impact of tobacco use and sociodemographic factors on mortality in pancreatic cancer in the United States: A time trend analysis.
e16432 Background: Significant advancements in pancreatic cancer treatment have improved survival, yet mortality remains high due to disease complexity. T...
Decoding anterior tongue carcinoma beyond TNM: Indian multi-centric, real-world data on molecular profiling and immunity in relation to clinical outcome—A divide, dive deep, and conquer approach.
e18054 Background: Anterior tongue cancer is predominant in Asia, particularly India. Locally advanced anterior tongue cancer exhibits poor outcomes, with...
Harnessing social media for cancer prevention and early detection: Challenges, opportunities, and pathways to equity.
9040 Background: Social media is a valuable tool for cancer prevention and early detection but faces challenges like gender disparities, misinformation, a...
Dalpiciclib combined with chidamide and letrozole as neoadjuvant therapy for HR-positive, HER2-negative early or locally advanced breast cancer: A single-arm, prospective, exploratory clinical study.
e12593 Background: Hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) exhibits lower rates of pat...
Postmarketing safety of loratinib: An analysis of the FDA Adverse Event Reporting System (FAERS).
e24103 Background: Mesenchymal lymphoma kinase (ALK) gene mutation inhibitors are highly effective treatments for ALK-positive lung cancer. We performed a...
Multi-omics evaluation of relapsed pediatric cancers: What information do these sequential analyses yield?
10047 Background: While cure rates for children with cancer have significantly improved, relapses remain a challenge, requiring deeper understanding to ad...
EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
4571 Background: EV-302/KEYNOTE-A39 (NCT04223856) demonstrated superior efficacy of first-line (1L) EV+P vs chemo and established EV+P as the standard of...
Reduction of postoperative radiotherapy in head and neck squamous cell carcinoma: A single-arm, phase II trial (REPORT-HNSCC study).
TPS6116 Background: Postoperative radiotherapy (PORT) significantly enhances the prognosis for high-risk patients with locally advanced squamous cell carc...
Impact of pre-treatment counseling on uptake of hormone replacement therapy in patients undergoing chemoradiation for cervical cancer.
5519 Background: Chemoradiation therapy (CRT) for cervical cancer can lead to premature ovarian insufficiency (POI) in premenopausal women, accelerating t...
MRD to identify no evidence of disease status in advanced breast cancer with CR.
e13034 Background: Although advanced breast cancer remains to be considered as uncurable, an increasing number of patients achieved long-term complete rem...
The unseen burden of CTCL caregiving.
e19059 Background: Cutaneous T-cell lymphoma (CTCL) patients rely heavily on informal caregivers for complex psychosocial and medical support. While cruci...
Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab.
8503 Background: Despite the approval of amivantamab (ami) for EGFR exon 20 insertion (ex20ins) mutant NSCLC, an unmet nee...
Efficacy and safety of immunotherapy or antiangiogenic agents-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A network meta-analysis.
e14599 Background: Immunotherapy with chemotherapy is recommended as standard first-line therapy for extensive-stage small lung cancer (ES-SCLC) patients....
Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): Primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial.
4009 Background: OSE2101 is an off the shelf vaccine made of 10 synthetic HLA-A2-restricted peptides targeting 5 tumor associated antigens. This multicent...
Prognostic assessment of pre- and post-neoadjuvant SUVs via 18F-FDG PET/CT in esophageal cancer patients.
e16003 Background: Esophageal cancer (EC) ranks as the seventh most common cancer globally, with a particularly high prevalence in middle- and low-income...
Predictive value of TTMV HPV DNA kinetics in induction chemotherapy in HPV-positive head and neck squamous cell carcinoma.
e18057 Background: Tumor tissue-modified viral (TTMV) HPV DNA is a sensitive, highly specific biomarker for human papillomavirus-positive (HPV+) head and...
A phase I clinical trial of ABP1019A monotherapy in patients with advanced malignant solid tumors.
e15147 Background: ABP1019A is an innovative tyrosine kinase inhibitor (TKI) that effectively inhibits EGFR, FGFR1-4, VEGFR1-3, RET, PDGFR-α, and CSF-1R....
Time to subsequent therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) receiving dostarlimab plus carboplatin-paclitaxel (DOST+CP) compared with pts receiving placebo plus CP (PBO+CP) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
5601 Background: In Part 1 of the phase 3 RUBY trial (NCT03981796), DOST+CP significantly improved progression-free survival (PFS) and overall survival (O...
Real-world patient (pt) characteristics, treatment patterns, and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC): Insights by <i>PTEN</i> status.
5096 Background: The loss of function of the tumor suppressor gene PTEN is associa...
Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib (A), in combination with encorafenib (E) and cetuximab (C) in patients (pts) with previously treated <i>BRAF V600E</i> mutantmetastatic colorectal cancer (mCRC).
3551 Background: Encorafenib + cetuximab was approved for treating pts with BRAF V600E mutant mCRC after...
Preliminary safety, pharmacokinetics, and clinical activity of RG6344 in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
3542 Background: RG6344 (RO7276389) is a novel paradox breaker and brain penetrant BRAF inhibitor (BRAFi) designed to overcome the MAPK paradoxical activi...
Stepwise AI prompting for multiple myeloma imaging classification.
e13707 Background: Electronic Health Records (EHRs) contain numerous variables, much of which are unstructured narrative data, posing challenges for syste...
Enhancing bereavement education and emotional preparedness: A global survey of oncology residency programs.
9031 Background: Bereavement care is a vital yet underemphasized aspect of oncology, requiring both clinical expertise and emotional resilience. Despite i...